Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
01:50a FOREFRONT : 885) to issue bonus shares on 9-for-1 basis
01:50a CHINA POWER DEV : sells 1.88% stake in Shanghai Electric Power
01:50a BRIGHTOIL PETROLEUM : sees increase in output of two gas fields
01:50a BLOOMAGE BIOTECHNOLOGY : BioTec buys medical aesthetics devices business
01:50a LE SAUNDA : mulls share premium reduction
01:50a MEGA EXPO : placing deal lapsed
01:50a LINMARK : in talks for shares subscription
01:50a CANVEST ENVIRONMENTAL PRTCTN GP : Env buys waste-to-energy plant at Rmb73.3m
01:50a SHENGUAN : major holder Rich Top Future adds 2m shares
01:50a DAIWA : raises Lenovo Group to HK$12.6
Latest news
Advertisement
Hot News 
TIME WARNER CABLE : INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Time Warner Cable Inc.
Charter's Time Warner Cable bid faces $2 billion regulatory question
MCDERMOTT : awarded project for 12 jackets offshore Saudi Arabia
LIBERTY BROADBAND : Malone nets his prey
VINCE : Announces Reporting Date For First Quarter 2015 Financial Results
Most Read News
05/26DJSINGAPORE AIRLINES : Flight to Shanghai on Saturday Temporarily Lost Engine Power, Landed Safely
05/26 Air Canada to redeploy capital as pension funding gap evaporates
05/26DJGRAIN HIGHLIGHTS : Top Stories Of The Day
05/26 NICO : Established: NICL board of directors appointed
05/26 BHP BILLITON : Constitutional Recognition
Most recommended articles
01:49a JAZZTEL : France's Orange wins Spanish approval for Jazztel purchase
01:47a Blocked in China, Twitter still courts Chinese firms for ads
01:42a BOJ's Iwata says timing for hitting price goal 'somewhat delayed'
01:35aDJU.S. Alleges Corruption At International Soccer Body FIFA
01:25aDJBelgian Court Summons Skype Over Refusal to Allow Wiretaps